Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Traws Pharma (TRAW) over the last 12 years, with Q3 2025 value amounting to $7.9 million.

  • Traws Pharma's Total Non-Current Liabilities changed N/A to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year change of. This contributed to the annual value of $14.1 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Traws Pharma's Total Non-Current Liabilities stood at $7.9 million.
  • In the past 5 years, Traws Pharma's Total Non-Current Liabilities registered a high of $14.1 million during Q4 2024, and its lowest value of $7.4 million during Q2 2025.
  • Over the past 3 years, Traws Pharma's median Total Non-Current Liabilities value was $11.0 million (recorded in 2021), while the average stood at $10.7 million.
  • The largest annual percentage gain for Traws Pharma's Total Non-Current Liabilities in the last 5 years was 484.41% (2021), contrasted with its biggest fall of 1199.12% (2021).
  • Quarter analysis of 3 years shows Traws Pharma's Total Non-Current Liabilities stood at $10.9 million in 2021, then rose by 29.88% to $14.1 million in 2024, then plummeted by 44.06% to $7.9 million in 2025.
  • Its Total Non-Current Liabilities was $7.9 million in Q3 2025, compared to $7.4 million in Q2 2025 and $12.9 million in Q1 2025.